Literature DB >> 7565137

A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies.

C Oeuvray1, H Bouharoun-Tayoun, H Grass-Masse, J P Lepers, L Ralamboranto, A Tartar, P Druilhe.   

Abstract

We report the identification of a 48kDa antigen targeted by antibodies which inhibit Plasmodium falciparum in vitro growth by cooperation with blood monocytes in an ADCI assay correlated to the naturally acquired protection. This protein is located on the surface of the merozoite stage of P. falciparum, and is detectable in all isolates tested. Epidemiological studies demonstrated that peptides derived from the amino acid sequence of MSP-3 contain potent B and T-cell epitopes recognized by a majority of individuals living in endemic areas. Moreover human antibodies either purified on the recombinant protein, or on the synthetic peptide MSP-3b, as well as antibodies raised in mice, were all found to promote parasite killing mediated by monocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7565137     DOI: 10.1590/s0074-02761994000600018

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  29 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

3.  The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites.

Authors:  Benjamin L Rice; Mónica M Acosta; M Andreína Pacheco; Jane M Carlton; John W Barnwell; Ananias A Escalante
Journal:  Mol Phylogenet Evol       Date:  2014-05-23       Impact factor: 4.286

4.  Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.

Authors:  L Wang; T L Richie; A Stowers; D H Nhan; R L Coppel
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Antibody responses to 43 and 48 kDa antigens of blood-stage Plasmodium berghei in Balb/c mice.

Authors:  Upma Bagai; Anil Pawar; Vineet Kumar
Journal:  J Parasit Dis       Date:  2010-10-08

6.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.

Authors:  J C Lima-Junior; J Jiang; R N Rodrigues-da-Silva; D M Banic; T M Tran; R Y Ribeiro; V S E Meyer; S G De-Simone; F Santos; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

7.  A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain.

Authors:  V M Marshall; A Silva; M Foley; S Cranmer; L Wang; D J McColl; D J Kemp; R L Coppel
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

8.  Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.

Authors:  Christian Roussilhon; Philippe Brasseur; Patrice Agnamey; Jean-Louis Pérignon; Pierre Druilhe
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

9.  Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment.

Authors:  Stephen J Jordan; OraLee H Branch; Juan Carlos Castro; Jean Carlos Castro; Robert A Oster; Julian C Rayner
Journal:  Am J Trop Med Hyg       Date:  2009-03       Impact factor: 2.345

10.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.